72
Participants
Start Date
November 17, 2017
Primary Completion Date
November 17, 2021
Study Completion Date
November 17, 2021
Onvansertib
Onvansertib orally
Cytarabine
subcutaneously
Decitabine
intravenously
Roswell Park Cancer Institute, Buffalo
Virginia Cancer Specialists - Fairfax Office, Fairfax
Allina Health Virginia Piper Cancer Institute, Minneapolis
University of Kansas Cancer Center, Westwood
University of Texas Southwestern Medical Center, Dallas
MD Anderson Cancer Center, Houston
University of California Los Angeles, Los Angeles
Seattle Cancer Care Alliance, Seattle
Yale University, New Haven
Lead Sponsor
Cardiff Oncology
INDUSTRY